Molecular structure of (S)-(−)-Carvedilol, CAS Number: 95094-00-1
(S)-(−)-Carvedilol (CAS 95094-00-1)
See product citations (3)
CAS Number:
95094-00-1
Molecular Weight:
406.47
Molecular Formula:
C24H26N2O4
Supplemental Information:
This is as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Carvedilol′s optically active isomer, exhibiting nonselective β-adrenergic blocking activity with concurrent a1-blocking activity. Experiments show antihypertensive properties, making it useful in the treatment of congestive heart failure.
(S)-(−)-Carvedilol (CAS 95094-00-1) References
- Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. | Horiuchi, I., et al. 2008. Biol Pharm Bull. 31: 976-80. PMID: 18451529
- General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol. | Hirohashi, M., et al. 1990. Arzneimittelforschung. 40: 735-46. PMID: 1977393
- Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes. | Takekuma, Y., et al. 2012. Biol Pharm Bull. 35: 151-63. PMID: 22293344
- Enantioselective Resolution of (R,S)-Carvedilol to (S)-(-)-Carvedilol by Biocatalysts. | Ettireddy, S., et al. 2017. Nat Prod Bioprospect. 7: 171-179. PMID: 28064425
- Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats. | Wu, T., et al. 2019. J Appl Toxicol. 39: 1233-1244. PMID: 31066085
- Optimization of lipid materials in the formulation of S-carvedilol self-microemulsifying drug-delivery systems. | Zhang, Q., et al. 2020. Drug Dev Ind Pharm. 46: 1507-1516. PMID: 32806972
- Prevention of Skin Carcinogenesis by the Non-β-blocking R-carvedilol Enantiomer. | Liang, S., et al. 2021. Cancer Prev Res (Phila). 14: 527-540. PMID: 33648941
- Preparation, Characterization, and Selection of Optimal Forms of (S)-Carvedilol Salts for the Development of Extended-Release Formulation. | Zhang, Q., et al. 2021. Mol Pharm. 18: 2298-2310. PMID: 34032449
- Impact of R-Carvedilol on β2-Adrenergic Receptor-Mediated Spontaneous Calcium Release in Human Atrial Myocytes. | Casabella-Ramón, S., et al. 2022. Biomedicines. 10: PMID: 35885069
- Effect of Roux-En-Y Gastric Bypass in the Pharmacokinetics of (R)-Carvedilol and (S)-Carvedilol. | Yamamoto, PA., et al. 2023. J Clin Pharmacol. 63: 838-847. PMID: 36854819
- Enantioselective binding of carvedilol to human serum albumin and alpha-1-acid glycoprotein. | Toma, CM., et al. 2023. Chirality. 35: 779-792. PMID: 37221930
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(S)-(−)-Carvedilol, 5 mg | sc-212831 | 5 mg | $360.00 |